Form 4: AnaptysBio Director Owen Hughes Receives RSU Grant

Director Owen Hughes was granted 11,250 restricted stock units in AnaptysBio, Inc. as part of standard equity compensation.

Summary

• Director Owen Hughes acquired 11,250 restricted stock units (RSUs) on May 11, 2026.
• Each RSU represents a contingent right to receive one share of AnaptysBio common stock.
• The grant was issued for no consideration.
• The RSUs vest in three equal annual installments starting May 11, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Equity-based compensation aligns the interests of the director with those of shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon the settlement of the RSUs.

Risks

• Vesting is subject to the continued service of the director, which could be impacted by unforeseen departures.

Future Outlook

The RSUs will vest in equal annual installments over three years, provided the director remains in service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure long-term retention and alignment with corporate governance best practices.

Comparison to Industry Standards

• The grant size and three-year vesting schedule are consistent with standard compensation packages for directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future settlement of the RSUs.

Next Steps

• Vesting of the first tranche of RSUs on May 11, 2027.

Key Dates

Keywords

AnaptysBio, ANAB, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units